Pirtobrutinib efficacy in covalent BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: Additional patients and extended follow-up from BRUIN

被引：0

作者：

Munir, Talha ^{[1
]}

Mato, Anthony R. ^{[2
]}

Woyach, Jennifer A. ^{[3
]}

Brown, Jennifer R. ^{[4
,5
]}

Ghia, Paolo ^{[6
,7
]}

Patel, Krish ^{[8
]}

Eyre, Toby A. ^{[9
]}

Lech-Maranda, Ewa ^{[10
]}

Lamanna, Nicole ^{[11
]}

Tam, Constantine S. ^{[12
,13
]}

Seymour, John F. ^{[12
,13
]}

Shah, Nirav N. ^{[14
]}

Coombs, Catherine C. ^{[15
]}

Ujjani, Chaitra S. ^{[16
]}

Patel, Manish R. ^{[17
]}

Fakhri, Bita ^{[18
]}

Cheah, Chan Y. ^{[19
,20
]}

Alencar, Alvaro J. ^{[21
]}

Cohen, Jonathon B. ^{[22
]}

Gerson, James N. ^{[23
]}

Flinn, Ian W. ^{[24
]}

Ma, Shuo ^{[25
]}

Jagadeesh, Deepa ^{[26
]}

Rhodes, Joanna M. ^{[27
]}

Hernandez-Ilizaliturri, Francisco ^{[28
]}

Zinzani, Pier Luigi ^{[29
]}

Balbas, Minna ^{[30
]}

Nair, Binoj ^{[30
]}

Abada, Paolo ^{[30
]}

Wang, Chunxiao ^{[31
]}

Wang, Denise ^{[30
]}

Tsai, Donald E. ^{[30
]}

Wierda, William G. ^{[32
]}

Jurczak, Wojciech ^{[33
]}

机构：

[1] St James Hosp, Leeds, W Yorkshire, England

[2] Mem Sloan Kettering Canc Ctr, New York, NY USA

[3] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA

[4] Dana Farber Canc Inst, Boston, MA USA

[5] Harvard Med Sch, Boston, MA USA

[6] Univ Vita Salute San Raffaele, Milan, Italy

[7] IRCCS Osped San Raffaele, Milan, Italy

[8] Swedish Canc Inst, Ctr Blood Disorders & Cellular Therapy, Seattle, WA USA

[9] Oxford Univ Hosp NHS Fdn Trust, Churchill Canc Ctr, Oxford, England

[10] Inst Hematol & Transfus Med, Warsaw, Poland

[11] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA

[12] Peter MacCallum Canc Ctr, Melbourne, Australia

[13] Univ Melbourne, Melbourne, Australia

[14] Med Coll Wisconsin, Milwaukee, WI USA

[15] Univ North Carolina Chapel Hill, Chapel Hill, NC USA

[16] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA

[17] Florida Canc Specialists Sarah Cannon Res Inst, Sarasota, FL USA

[18] Univ Calif San Francisco, San Francisco, CA USA

[19] Linear Clin Res, Perth, Australia

[20] Sir Charles Gairdner Hosp, Perth, Australia

[21] Univ Miami, Miller Sch Med, Miami, FL USA

[22] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[23] Univ Penn, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA USA

[24] Sarah Cannon Res Inst, Nashville, TN USA

[25] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL USA

[26] Cleveland Clin, Cleveland, OH USA

[27] Northwell Hlth, Northwell Hlth Canc Inst, Donald & Barbara Zucker Sch Med Hofstra, New Hyde Pk, NY USA

[28] Roswell Pk Comprehens Canc Ctr, Lymphoma Sect, Dept Med Oncol, Buffalo, NY USA

[29] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[30] Loxo Lilly, Indianapolis, IN USA

[31] Eli Lilly & Co, Indianapolis, IN USA

[32] MD Anderson Canc Ctr, Houston, TX USA

[33] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BSH23-PO84

引用

页码：110 / 111

页数：2

共 50 条

[31] Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor
Gilles Salles
Jenny M. H. Chen
Ina Zhang
Fabio Kerbauy
James J. Wu
Sally W. Wade
Ana Nunes
Chaoling Feng
Ioana Kloos
Weimin Peng
Julia T. Snider
Dylan Maciel
Keith Chan
Sam Keeping
Bijal Shah
Advances in Therapy, 2024, 41 : 1938 - 1952
[32] Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor
Salles, Gilles
Chen, Jenny M. H.
Zhang, Ina
Kerbauy, Fabio
Wu, James J.
Wade, Sally W.
Nunes, Ana
Feng, Chaoling
Kloos, Ioana
Peng, Weimin
Snider, Julia T.
Maciel, Dylan
Chan, Keith
Keeping, Sam
Shah, Bijal
ADVANCES IN THERAPY, 2024, 41 (05) : 1938 - 1952
[33] Long-Term Follow-up with GS-4059, a Selective Irreversible BTK Inhibitor, in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia
Walter, Harriet S.
Jayne, Sandrine
Rule, Simon A.
Cartron, Guillaume
Morschhauser, Franck
Fegan, Christopher
Yang, Yingsi
Mitra, Siddhartha
Dyer, Martin J. S.
Salles, Gilles A.
BLOOD, 2016, 128 (22)
[34] The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study
O'Brien, Susan
Burger, Jan A.
Blum, Kristie A.
Furman, Richard R.
Coutre, Steven E.
Sharman, Jeff
Flinn, Ian W.
Grant, Barbara
Heerema, Nyla A.
Johnson, Amy J.
Navarro, Tasheda
Holmgren, Eric
Hedrick, Eric
Byrd, John C.
BLOOD, 2011, 118 (21) : 449 - 450
[35] Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004
Siddiqi, Tanya
Gauthier, Jordan
Kenderian, Saad S.
Brander, Danielle M.
Dorritie, Kathleen
Soumerai, Jacob D.
Reidell, Peter A.
Shah, Nirav N.
Nath, Rajneesh
Andreadis, Charalambos
Ermann, Daniel A.
Ma, Shuo
Feldman, Tatyana
Solomon, Scott R.
Schuster, Stephen J.
Tuazon, Sherilyn A.
Perna, Serena K.
Ou, San-San
Rane, Neha
Papp, Eniko
Chen, Yizhe
Wierda, William G.
BLOOD, 2024, 144 : 4633 - 4635
[36] Safety and Efficacy of Tinostamustine in Pre-Treated Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL): Early Results from an Additional Expansion Cohort of a Phase I Study
Sureda, Anna
Pinto, Antonio
Ghesquieres, Herve
Morschhauser, Franck
Tournilhac, Olivier
Mutseaers, Pim
Zijlstra, Josee M.
De Jong, Floris A.
Janik, Tomas
Zinzani, Pier Luigi
BLOOD, 2022, 140 : 3696 - 3697
[37] Real-World Results on Ibrutinib in Relapsed/Refractory CLL: A 21-Month Follow-up of 95 Swedish Patients Treated in a Compassionate Use Program
Winqvist, Maria
Andersson, Per-Ola
Asklid, Anna
Karlsson, Karin
Karlsson, Claes
Lauri, Birgitta
Lundin, Jeanette
Mattsson, Mattias
Norin, Stefan
Sandstedt, Anna Bergendahl
Hansson, Lotta
Osterborg, Anders
BLOOD, 2017, 130
[38] Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma - Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center
Momotow, Jesko
Goergen, Helen
Behringer, Karolin
Broeckelmann, Paul J.
Borchmann, Sven
Tresckow, Bastian V.
Kobe, Carsten
Engert, Andreas
Sasse, Stephanie
HEMASPHERE, 2019, 3 (05):
[39] Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naive Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study
Greil, Richard
Fraser, Graeme
Leber, Brian
Marks, Reinhard
Quaresmini, Giulia
Middeke, Jan Moritz
Semenzato, Gianpietro
Schary, William
Boyer, Michelle
Breuleux, Madlaina
Crompton, Noelle
Humphrey, Kathryn
Marlton, Paula
BLOOD, 2018, 132
[40] Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor: Primary Analysis from a Phase 2 Study (CITADEL-205)
Mehta, Amitkumar
Trneny, Marek
Walewski, Jan
Ribrag, Vincent
Dartigeas, Caroline
Christensen, Jacob Haaber
Pane, Fabrizio
Rodriguez, Guillermo
Taszner, Michal
Venugopal, Parameswaran
Zilioli, Vittorio Ruggero
Zheng, Fred
DeMarini, Douglas J.
Jiang, Wei
Zinzani, Pier Luigi Luigi
BLOOD, 2021, 138

← 1 2 3 4 5 →